Monte Rosa Therapeutics is a biopharmaceutical company. Co. has developed a protein degradation platform, called QuEEN (Quantitative and Engineered Elimination of Neosubstrates), to enable its target-centric approach to its molecular glue degraders (MGDs) discovery and development. Co.'s QuEEN platform enables it to identify protein targets and associated MGD product candidates that are designed to eliminate therapeutically-relevant proteins. Co.'s primary candidate, MRT-2359, is an orally bioavailable degrader of the translation termination factor protein GSPT1 in development initially for use in the treatment of cancers overexpressing one of the Myc family genes (c-Myc, N-Myc and L-Myc). The GLUE YTD return is shown above.
The YTD Return on the GLUE YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether GLUE YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GLUE YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|